Medexus Announces $20 Million Bought Deal Public Offering of Units
February 02, 2021 15:03 ET
|
Medexus Pharmaceuticals Inc
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, CHICAGO and MONTREAL, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc....
Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell Transplantation, Treosulfan, in the United States
February 02, 2021 14:21 ET
|
Medexus Pharmaceuticals Inc
Orphan Designated Drug with August 2021 PDUFA date Management to host conference call at 10:00 AM Eastern Time on February 3, 2021 and Key Opinion Leader webinar to be held at 2:00 PM Eastern Time...
Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA®
January 25, 2021 08:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO, CHICAGO and MONTREAL, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has...
Medexus Submits Application to List on the Nasdaq
January 21, 2021 08:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO, CHICAGO and MONTREAL, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has...
Medexus Engages Independent Trading Group for Market Making Services
January 06, 2021 17:00 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO and MONTREAL, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it has...
Medexus Announces Annual Equity Incentive Grants to Non-Executive Directors
December 21, 2020 17:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO and MONTREAL, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that the...
Medexus Enters into Exclusive License to Register and Commercialize Triamcinolone Hexacetonide (TH) in the United States with Ethypharm
December 18, 2020 08:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO and MONTREAL, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to announce it...
Medexus to Present at The 13th Annual LD Micro Main Event Conference on December 15th
December 08, 2020 08:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO and MONTREAL, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF), today announced that it will be presenting at...
Medexus Pharmaceuticals Reports Operating and Financial Results for the Three- and Six-Month Periods Ending September 30, 2020
November 16, 2020 17:15 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO and MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced its financial and...
Medexus Reaches 50% Enrollment in IXINITY® Phase 4 Clinical Trial Targeting Label Expansion for Pediatric Hemophilia B Patients
November 16, 2020 08:00 ET
|
Medexus Pharmaceuticals Inc
TORONTO, CHICAGO and MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF) today announced it has reached the 50%...